Loading provider…
Loading provider…
Hematology & Oncology Physician in New Haven, CT
NPI: 1407021140Primary Practice Location
YALE-NEW HAVEN HOSPITAL
35 Park St, New Haven, CT
Primary Employer
Yale Medicine
yalemedicine.org
HQ Phone
Get M.D. Iris's Phone Numberphone_androidMobile
Get M.D. Iris's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCT State Medical License
Yale University
fellowship • Hematology and Medical Oncology
2008 - 2011
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 96 | 164 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 87 | 229 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 21 | 65 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 18 | 105 |
| 5 | 99205New patient office or other outpatient visit, typically 60 minutes | 15 | 15 |
Authors: Stuart Seropian, Lohith Gowda, Jan Philipp Bewersdorf, Amer Zeidan, Nikolai Podoltsev
Journal: Leuk Lymphoma
Publication Date: 2020-05-02
Authors: Ian Flinn, Ranjana Advani, Jason Kaplan, Michael Pourdehnad, Vaishalee Kenkre, Julio Chavez
Journal: EJHaem
Publication Date: 2022-01-14
Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant.
Authors: Stuart Seropian, Alfredo Axtmayer, Lohith Gowda, Shalin Kothari, Francine Foss, Stephanie Halene
Journal: PLoS One
Publication Date: 2025-04-28
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Lenalidomide, BIOLOGICAL: Blinatumomab
Lead Sponsor: Marker Therapeutics, Inc.
Intervention / Treatment: DRUG: MT-401
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT), DRUG: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy